Article
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Blood advances - 24 Mar 2020
Jain Preetesh, Zhang Shaojun, Kanagal-Shamanna Rashmi, Ok Chi Young, Nomie Krystle, Gonzalez Graciela Nogueras, Gonzalez-Pagan Omarya, Hill Holly A, Lee Hun Ju, Fayad Luis, Westin Jason, Nastoupil Loretta, Hagemeister Frederick, Chen Wendy, Oriabure Onyeka, Badillo Maria, Jiang Changying, Yixin Yao, Li Shaoying, Tang Guilin, Yin C Cameron, Patel Keyur P, Medeiros Leonard Jeffrey, Nair Ranjit, Ahmed Sairah, Iyer Swaminathan P, Thirumurthi Selvi, Champlin Richard, Xu Guofan, Tinsu Pan, Santos David, Wang Ruiping, Han Guangchun, Zhang Jianhua, Song Xingzhi, Neelapu Sattva, Romaguera Jorge, Futreal Andy, Flowers Christopher, Fowler Nathan, Wang Linghua, Wang Michael L
Abstract excerpt
Blastoid and pleomorphic mantle cell lymphomas (MCLs) are variants of aggressive histology MCL (AH-MCL). AH-MCL can arise de novo (AH-DN) or transform from prior classic variant MCL (AH-t). This study is the first integrated analysis of clinical and genomic characteristics of AH-MCL. Patient characteristics were collected from diagnosis (AH-DN) and at transformation (AH-t). Survival after initial diagnosis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.